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The effect of above-normal body mass index (BMI) on health outcomes is controversial 
because it is difficult to distinguish from the effect due to BMI-associated 
cardiovascular risk factors. The objective was to analyze the impact on 10-year 
incidence of cardiovascular disease, cancer deaths and overall mortality of the 
interaction between cardiovascular risk factors and BMI. We conducted a pooled 
analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. 
Participants had no previous history of cardiovascular diseases and were 35–79 years 
old at basal examination. Body mass index was measured at baseline being the outcome 
measures ten-year cardiovascular disease, cancer and overall mortality. Multivariable 
analyses were adjusted for potential confounders, considering the significant 
interactions with cardiovascular risk factors. We included 54,446 individuals (46.5% 
with overweight and 27.8% with obesity). After considering the significant interactions, 
the 10-year risk of cardiovascular disease was significantly increased in women with 
overweight and obesity [Hazard Ratio=2.34 (95% confidence interval: 1.19-4.61) and 
5.65 (1.54-20.73), respectively]. Overweight and obesity significantly increased the risk 
of cancer death in women [3.98 (1.53-10.37) and 11.61 (1.93-69.72)]. Finally, obese 
men had an increased risk of cancer death and overall mortality [1.62 (1.03-2.54) and 
1.34 (1.01-1.76), respectively]. In conclusion, overweight and obesity significantly 
increased the risk of cancer death and of fatal and non-fatal cardiovascular disease in 
women; whereas obese men had a significantly higher risk of death for all causes and 
for cancer. Cardiovascular risk factors may act as effect modifiers in these associations.  





Obesity is a worldwide public health problem due to its high prevalence, the 
epidemic increase observed in recent decades, and the associated diseases (GBD 2015 
Obesity Collaborators, 2017; Finucane, 2011; Guh, 2009). The World Health 
Organization (WHO) reports that more than 1.9 billion adults were overweight in 2014, 
and more than 600 million of these individuals were obese, doubling the worldwide 
prevalence of obesity since 1980 (Global Database on Body Mass Index, 2017). Recent 
projections are that global obesity prevalence will reach 18% in men and surpass 21% 
in women by 2025; severe obesity will exceed 6% in men and 9% in women (NCD Risk 
Factor Collaboration, 2016). Finally, overweight and obesity, estimated with body mass 
index (BMI, calculated as weight in kilograms divided by height in meters squared), 
have been associated with decreased functional ability and health status and increased 
risk of chronic conditions in classical observational studies (Guh, 2009; Fontaine, 2003; 
Prospective Studies Collaboration, 2009; Stenholm, 2016) and in Mendelian 
randomization studies (Carreras-Torres, 2017; Carreras-Torres, 2017; Holmes, 2014; 
Thrift, 2015). Although BMI is well established as a risk factor or indicator, the direct 
effect of above-normal BMI on health outcomes remains controversial (Gao C. Int J 
Epidemiol. 2016; Mandviwala T. Curr Atheroscler Rep. 2016). This effect could be 
secondary, through an influence on the development and severity of cardiovascular risk 
factors (CRF) such as hypertension, diabetes, and hypercholesterolemia (Bogers, 2007; 
Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, 2014; 
Jerant, 2012; Poirier P. Circulation. 2006). However, it may also occur in the absence of 
CRF and may be due to structural and functional changes in excess adipose tissue 
deposition or to underlying mechanisms that remain unknown (Global Burden of 
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Metabolic Risk Factors for Chronic Diseases Collaboration, 2014; Mandviwala T. Curr 
Atheroscler Rep. 2016; Gao C. Int J Epidemiol. 2016). Teasing apart the effect on 
health outcomes of above-normal BMI from other comorbidities requires a population-
based cohort with an appropriate sample size, long follow-up, and an exhaustive register 
of outcomes. Obtaining this information is essential to design effective preventive 
measures.  
The objectives of the present study are: (1) to ascertain the association of BMI and 
different BMI cut-off points with 10-year cardiovascular disease (CVD) incidence and 
with cancer and overall mortality in a population-based cohort of more than 54,000 
participants, and (2) to describe the interaction of CRF in the association between 
above-normal BMI values and the risk of all three outcomes.  
 
2. Methods 
2.1 Design and participants 
We conducted a pooled analysis of anonymized individual data from 12 population 
cohorts in 7 Spanish regions, examined between 1992 and 2005 with similar methods; 
the methodology of this cohort study has been explained elsewhere (Marrugat, 2014). In 
summary, all participants in the FRESCO cohorts were randomly selected and included 
participants without previous symptoms or diagnosis of CVDs, aged 35 to 79 years 
(Supplementary Table 1). The FRESCO study was approved by the local Ethics 
Committee of the Parc de Salut Mar (authorization #: 2009/3391/I). All participants 






CRF were measured at baseline using standardized methods based on World Health 
Organization recommendations (Tunstall-Pedoe, 1994). A precision scale of easy 
calibration was used for weight measurement with participants in underwear. Height 
was measured with a standard measuring rod, with participants standing barefoot. BMI 
was determined as weight divided by squared height (kg/m2). Using a standardized 
smoking questionnaire, participants were classified as smokers (current or quit <1 year) 
or nonsmokers (quit ≥1 year or never smoked).  
Blood was withdrawn after 10–14 hours fasting. Total and high-density lipoprotein 
(HDL) cholesterol concentrations were measured in serum sample aliquots stored at 
−80°C. The Friedewald formula was used to estimate low-density lipoprotein (LDL) 
cholesterol whenever triglycerides were <300 mg/dl. A previous study, in which 9 of 
the 12 FRESCO cohorts participated, obtained good agreement in the measurement of 
frozen samples from a random subset of participants, establishing that the study’s 
laboratory measurements can be reliably pooled (Grau, 2011). Blood pressure was 
determined from the average of 2 separate readings taken at least 5 min apart. 
Hypertension, diabetes, hypercholesterolemia and type of treatment were self-reported 
by the participants in all studies. We also considered hypertension whenever an 
individual presented with systolic or diastolic blood pressure ≥140/90 mmHg, 
respectively; diabetic those participants in whom glycemia >125 mg/dl was observed at 
the time of baseline examination. In both cases, this condition was assigned regardless 






We defined three end-points for the purpose of our analysis: (1) CVD incidence: 
fatal or nonfatal myocardial infarction or stroke and angina pectoris; (2) Cancer 
mortality and (3) Overall mortality. Multiple sources were used to identify potential 
CVD cases, including self-report, re-examination, and linkages to primary care 
registers, hospital admissions, and regional and national mortality data. All nonfatal 
diagnoses were verified by examining the corresponding electronic medical record. 
Unstable angina during follow-up was diagnosed by the presence of angina symptoms 
without an abnormal increase in the cardiac enzymes or troponin and with relevant 
changes in serial electrocardiograms. Alternatively, with or without 
electrocardiographic changes, a diagnosis was made when suggestive symptoms were 
recorded during the event and confirmed either by a positive coronary angiography 
(stenosis > 70%) or by a positive stress test with or without isotopic stress 
gammagraphy (Marrugat, 2014).  
Vital status and causes of death during 10-year follow-up were ascertained by 
reviewing medical records and by linkage with the official death registry, coded 
according to the 10th revision of the International Classification of Diseases (ICD). 
Mortality was classified as due to CVD (ICD F01, I20-I25, I60-I69, G45), and all 
malignant neoplasms (ICD C00-C99, D1-D48) (Baena-Diez, 2016).  
 
2.4 Statistical analysis 
Three BMI categories were defined: (1) normal weight, BMI ≥18.5 and <25 kg/ m2; 
(2) overweight, BMI ≥25 and <30 kg/ m2; and (3) obesity, BMI ≥30 kg/m2.   
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Variables were summarized as mean and standard deviation (SD) and median and 
interquartile range (IQR) when the distribution departed from normal. Categorical 
variables were described as proportions. Chi-square was computed to test differences 
for categorical variables at baseline; analysis of variance and Kruskall-Wallis tests were 
used for variables that did and did not follow a normal distribution, respectively. Ten-
year differences in CVD incidence and in cancer and overall mortality by BMI 
categories at the end of the follow-up were computed by the Kaplan-Meier method. To 
assess the linear trend of variables by BMI categories, analysis of variance and chi-
square tests were used. BMI categories and CRF were also summarized by outcome. 
We tested the linearity of the association between continuous BMI and the risk of 
all three end-points considered. Adjusted Cox regression models were fitted whenever 
the result did not reveal a nonlinear component of the relationship.  
Effect modification of the relationship between sex, CRF (age, diabetes, 
hypertension, smoking, total and HDL cholesterol) and BMI categories and each end-
point was tested with the -2 log-likelihood test of nested models with and without 
interaction terms. Two multivariable sex-stratified models were fitted for each end-
point. The first was adjusted for age and the second was further adjusted for diabetes, 
hypertension, smoking, total and HDL cholesterol and for the significant interactions 
between the CRFs and BMI category. 
Sensitivity analysis was conducted using standard BMI categories: (1) normal 
weight, BMI ≥18.5 and <27 kg/m2, or BMI ≥25 and <27 kg/ m2 with no further CRF; 
(2) overweight, BMI ≥25 and <27 kg/ m2 with at least one additional CRF, or BMI ≥27 
and <30 kg/ m2; and (3) obesity, BMI ≥30 kg/m2. Additionally, we conducted a 
competing risk analysis (Fine & Gray regression) considering death due to CVD and 
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cancer. Finally, we reanalyzed the data after excluding angina from the definition of 
fatal and non-fatal CVD.  
All calculations were made with R statistical package (R Foundation for Statistical 
Computing, Vienna, Austria; version 3.3.2). 
 
3. Results 
The FRESCO cohort included 54,446 individuals with valid BMI measurements, of 
which 46.5% presented with overweight and 27.8% with obesity. Figure 1 shows the 
end-point distribution in all three BMI categories over the 10-year median follow-up 
(interquartile range 8.8-10). 
 
3.1 Cardiovascular risk profile according to BMI categories and to end-points 
Individuals with overweight or obesity were significantly older, less likely to 
smoke, and had higher systolic and diastolic blood pressure and total and LDL 
cholesterol, triglycerides and glycemia values, compared with normal-weight 
individuals, and more often presented with hypertension and diabetes. In the highest 
BMI categories, significantly higher crude rates of 10-year fatal and nonfatal CVD 
incidence, cancer mortality, and overall mortality were observed in women, but only 
CVD in men (Table 1).  
Individuals who presented with an outcome in the follow-up were, in general, older, 
less likely to smoke, and had higher systolic and glycemia values, compared with those 
who do not present, and more often presented with hypertension and diabetes 




3.2 Risk of adverse health outcomes by BMI values 
The age-adjusted association between BMI, as a continuous variable, and the risk of 
all three end-points showed a significant linear increasing trend for CVD incidence in 
both sexes. On the contrary, BMI significantly decreased the risk of cancer death and 
showed a U-shaped curve for overall mortality in men (Fig. 2).  
An analysis by BMI categories suggested the CRF that had a modification effect for 
all three end-points. Multivariable models were adjusted for these interactions. 
 
3.3 Risk of cardiovascular disease and death, by BMI category 
We found a significant effect modification of the relationship between sex, CRF 
(age, diabetes, hypertension, smoking, and total and HDL cholesterol), BMI categories, 
and each end-point in almost all -2 log-likelihood tests of nested models. After 
adjustment for potential confounders and for the interaction with age by categories of 
BMI, CVD-related risk was significantly higher in women with overweight or obesity, 
compared to normal weight [Hazard ratio=2.34 (95% confidence interval: 1.19-4.61) 
and 5.65 (1.54-20.73), respectively]. When the model was adjusted for the interaction 
with diabetes, by categories of BMI, the result was not significant in men. In women, 
overweight and obesity significantly increased the risk of cancer death after adjustment 
for the interaction with total cholesterol, by categories of BMI [3.98 (1.53-10.37) and 
11.61 (1.93-69.72), respectively]. In obese men, the risk of cancer death was also 
significantly increased, but with lower magnitude than in women with obesity [1.62 
(1.03-2.54)]. In this case, the model was further adjusted for the interaction with 
hypertension, by the categories of BMI. 
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After adjustment for the interaction with hypertension, a significant linear 
association was observed between overall mortality risk and BMI category in men; in 
women, the adjusted hazard ratio was marginally significant [1.35 (0.96-1.89)] (Tables 
3 and 4). Figure 3 describes the effect of the significant interactions on every outcome 
considered. 
 
3.4 Sensitivity analysis 
All sensitivity analyses yielded results similar to the primary analysis. On the one 
hand, Supplementary Tables 3-6 show the cardiovascular risk profile and the adverse 
health outcomes distribution according to a second BMI stratification, which considers 
the prevalence of CRF. Supplementary Table 7 shows the competing risks (Fine & Gray 
regression) of cause-specific deaths (CVD and cancer). Finally, the sensitivity analysis 
using a CVD end-point excluding angina is shown in Supplementary Table 8. 
 
4. Discussion 
Above-normal BMI has been associated with disability and premature mortality. In 
the present study, obesity increased the risk of fatal and non-fatal CVD events, cancer 
death, and overall mortality. Aging, hypertension, hypercholesterolemia, and diabetes 
may have a role as effect modifiers in these relationships, although the effect was 
confusing in individuals with those CRF. In individuals with no effect modification, 
above-normal BMI may act as an independent risk factor that follows a dose-response 
pattern, suggesting that there is no healthy pattern of increased weight (Kramer, 2013; 
Borrell, 2014). This observation may reflect, to some extent, the role of obesity as an 
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effect mediator between CRF and the development of adverse health outcomes (i.e., 
serving as a risk marker) (Mandviwala, 2016).  
 
4.1 BMI as a risk factor for cardiovascular disease 
In the age-adjusted analysis, BMI presents a clear relationship with fatal and 
nonfatal CVD. The role of obesity as an independent risk factor or a risk marker has 
long been discussed (Mandviwala, 2016). Obesity increases the risk of coronary artery 
disease (the most incident CVD event) secondarily through its influence on the 
development and severity of comorbidities such as diabetes, hypertension, or 
dyslipidemia, acting in these cases as a risk marker (Poirier, 2006). Inclusion of aging as 
an effect modifier showed that overweight and obesity in women were independent risk 
factors for fatal and non-fatal CVD. This analysis underlines the behavior of above-
normal BMI levels as an independent risk factor, in the absence of other effect 
modifiers.  
The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration 
study found that the association between adiposity and CVD was not completely 
explained by the three mediators studied (blood pressure, cholesterol, and glucose). The 
unexplained risk might be caused by other pathways, such as endothelial dysfunction, 
increase in thrombogenic factors, and the remaining effect of increased sympathetic 
activity and systemic inflammation not related to risk factors, which might be more 
important in individuals with obesity, compared to overweight (Global Burden of 
Metabolic Risk Factors for Chronic Diseases Collaboration, 2014). This significant 
effect was previously observed in young populations with coronary artery disease, 
which traditionally have had a greater prevalence of obesity (Choudhury, 1999). In the 
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CRUSADE registry, obesity was the strongest risk factor linked to non-ST elevation 
myocardial infarction events, followed by tobacco use (Madala, 2008). Long-term 
exposure to above-normal BMI leads to the development of CRF that may exceed the 
effect size of classical risk factors alone in calculating the risk of cardiovascular events 
(Yan, 2006; Twig, 2016). 
 
4.2 Overweight, obesity, and mortality 
We observed a U-shaped curve for the association between BMI values and overall 
mortality risk, particularly in men. This was the only outcome in which a linear trend 
was not observed. This characteristic shape has also been observed in the association 
between BMI values and CVD and overall mortality across different regions in the 
world (Chen, 2013; Berrington de Gonzalez, 2010; Global BMI Mortality 
Collaboration, 2010; Ponce-Garcia, 2015; Padwal, 2016; Yi, 2015). Previous analysis 
shows that clustering CRF (diabetes, hypertension, smoking, dyslipidemia) with obesity 
in statistical analysis may attenuate the effect size of the latter on health outcomes 
(Jerant, 2012). The mortality risk in individuals with overweight has been discussed 
with quite divergent results (Chen, 2013; Berrington de Gonzalez, 2010; Global BMI 
Mortality Collaboration, 2010; Ponce-Garcia, 2015; Padwal, 2016; Yi, 2015; Orpana, 
2010).  
Concurring with previous studies (Reeves, 2007; Renehan, 2010), cancer mortality 
risk increased dramatically in women with overweight and obesity, particularly in those 
with total cholesterol <220 mg/dl. These results underline the sex-related differences in 




4.3 Characteristics and limitations 
The FRESCO project is a pooled analysis of 12 population-based cohorts of 
individuals aged 35 to 79 years with two major strengths: the population 
representativeness and the comparativeness between all component studies that 
followed the MONICA standard guidelines to collect data (Tunstall-Pedoe, 1994). 
However, our study has several limitations. First, we used a single BMI measurement at 
baseline and did not consider any further measurements during the 10-year follow-up to 
monitor changes over time. Second, we did not consider other measures of obesity (e.g., 
abdominal circumference, waist-to-hip ratio); however, past collaborative studies 
including cohorts from all over the world have shown that BMI is in itself a strong 
predictor of overall mortality (Prospective Studies Collaboration, 2009; Global BMI 
Mortality Collaboration, 2010). Third, some variables with a potential effect on the BMI 
values and on the outcomes (e.g., social status, deprivation, alcohol use, physical 
activity, diet) were not collected in the FRESCO Project. Residual confounding is likely 
to exist in our analysis despite all our efforts. Additionally, the heterogeneity between 
the component cohorts in transient ischemic attack events, likely due to the difficulty of 
identifying the disorder, prevented its inclusion as an outcome of this analysis. Fourth, 
survival bias is inherent to cohort studies, and is likely to apply to the present analysis, 
especially among people recruited at older ages. This bias may hamper the validity of 
some of the associations observed, particularly in men because their life expectancy is 
lower than in women (INE, 2017). Finally, past studies have shown that changes in 
obesity and BMI take some time to affect incidence and mortality rates at a population 
level. For instance, in the context of the Framingham Heart Study, obesity was 
associated with increased relative risk for development of coronary artery disease in a 
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population, ages 35 to 75, over a 44-year follow-up (Wilson, 2002). In addition, a meta-
analysis has found that studies with more than 10 years of follow-up were more likely to 
observe a significant association between obesity and coronary artery disease (Bogers, 
2007). Nonetheless, our analysis, with a 10-year median follow-up, showed 
significantly higher mortality rates for all endpoints considered in individuals exposed 
to above normal BMI values, and particularly obesity. The use of Mendelian 
randomization methodology, in theory being less affected by bias or confounding, has 
the potential to establish a causal relationship between modifiable exposures and disease 
outcomes, compared to observational (non-genetic studies). This approach could help in 




Overweight and obesity significantly increased the risk of cancer death and of fatal 
and non-fatal cardiovascular disease in women; whereas obese men presented a 
significant higher risk of death from all causes and for cancer, specifically. Aging, 
diabetes, hypertension, and total cholesterol may act as effect modifiers in these 
associations.  
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Figure 1. Flow chart of the participants in the FRESCO Study (Spain).  
Figure 2. Age-adjusted risk of 10-year fatal and nonfatal cardiovascular disease 
incidence (A), cancer death (B), and overall mortality (C) by body mass index, stratified 
by sex in the FRESCO Study (Spain). 
Figure 3. Adjusted risk of 10-year fatal and nonfatal cardiovascular disease incidence 
(A), cancer death (B), and overall mortality (C), stratified by sex in the FRESCO Study 
(Spain). 
Models were adjusted for the cardiovascular risk factor included in the legend by 





Table 1. Baseline characteristics and outcomes of the participants in the FRESCO Study by sex by body mass index categories 
 Men Women 
 Body mass index  Body mass index  
 ≥18.5 & <25  
N=5448 






≥18.5 & <25  
N=8497 






Age, mean (SD) 54 (12) 56 (12) 56 (11) <0.001 51 (12) 57 (12) 59 (11) <0.001 
Smoker, n (%) 2074 (38.3) 3725 (27.6) 1745 (28.8) <0.001 1941 (23.0) 1235 (10.6) 602 (6.7) <0.001 
Systolic BP, mean (SD) 131 (18) 137 (18) 142 (19) <0.001 124 (20) 134 (20) 141 (20) <0.001 
Diastolic BP, mean (SD) 78 (9) 81 (9) 83 (10) <0.001 75 (9) 79 (9) 82 (9) <0.001 
Hypertension, n (%) 2139 (41.6) 7563 (58.3) 4272 (72.6) <0.001 2449 (30.6) 6093 (54.2) 6104 (70.7) <0.001 
Total cholesterol, mean (SD) 215 (40) 222 (40) 222 (41) <0.001 217 (41) 228 (42) 227 (41) <0.001 
HDL cholesterol, mean (SD) 53 (14) 49 (12) 47 (12) <0.001 63 (15) 58 (14) 54 (13) <0.001 
LDL cholesterol, mean (SD) 142 (38) 149 (38) 149 (38) <0.001 138 (39) 150 (40) 150 (39) <0.001 
Triglycerides, median [IQR] 90 [70-122] 106 [79-146] 119 [88-166] <0.001 74 [58-97] 91 [69-122] 108 [81-146] <0.001 
Glycemia, median [IQR] 94 [86-103] 98 [89-110] 102 [92-119] <0.001 88 [82-95] 92 [85-101] 97 [88-112] <0.001 
Diabetes, n (%) 679 (12.6) 2332 (17.4) 1540 (25.3) <0.001 531 (6.3) 1474 (12.6) 1983 (22.2) <0.001 
Fatal and non fatal 
cardiovascular disease*, n (%) 
254 (6.2) 731 (7.0) 417 (8.5) <0.001 152 (2.3) 360 (3.8) 328 (4.6) <0.001 
Cancer death*, n (%) 124 (2.4) 283 (2.2) 129 (2.3) 0.523 60 (0.8) 139 (1.2) 111 (1.3) 0.001 
Overall mortality*, n (%) 359 (6.9) 740 (5.8) 401 (6.9) 0.979 207 (2.6) 404 (3.6) 352 (4.0) <0.001 
Abbreviations: BP, Blood pressure; CRF, Cardiovascular risk factors; CVD, Cardiovascular disease; IQR, Interquartile range; HDL, High-density lipoprotein; LDL, Low-density 




Table 2. Hazard ratios for fatal and non-fatal cardiovascular disease, cancer death, and overall mortality among men with overweight or 
obesity, compared to normal weight, at baseline, estimated by Cox regression, after adjustment for potential risk factors and significant 
interactions. 
 Fatal and non-fatal cardiovascular 
disease 
Cancer death Overall death 
 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 















































































categories of BMI  
-- 0.75 
(0.63-0.89) 
-- -- -- -- 
Hypertension by 
categories of BMI  




Models were mutually adjusted 
CI, Confidence interval; HR, Hazard ratio
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Table 3. Hazard ratios for fatal and non-fatal cardiovascular disease, cancer death, and overall mortality among men with overweight or 
obesity, compared to normal weight at baseline, estimated by Cox regression, after adjustment for potential risk factors and significant 
interactions. 
 Fatal and non-fatal 
cardiovascular disease 
Cancer death Overall death 
 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 














































































Hypertension by categories of 
BMI  
-- -- -- -- -- 0.81 
(0.66-0.98) 
Age by categories of BMI -- 0.99 
(0.98-1.00) 
-- -- -- -- 
Total cholesterol by categories of 
BMI 
-- -- -- 0.95 
(0.92-0.99) 
-- -- 
Models were mutually adjusted 
CI, Confidence interval; HR, Hazard ratio   
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Figure 2.  
Men Women 
(A) Fatal and non-fatal cardiovascular disease incidence 
  
(B) Cancer mortality 
  




Figure 3.  
Men Women 
(A) Fatal and nonfatal cardiovascular disease incidence 
  
(B) Cancer mortality 
  
(C) Overall mortality 
  
 
